TERN
Terns Pharmaceuticals, Inc.
Key Financials
Revenue
$0
↓ 100.0%
Operating Income
$-110124000
↓ 8.1%
Net Income
$-96207000
↓ 8.3%
Total Liabilities
$18.6M
↑ 2.7%
Total Assets
$1.0B
↑ 181.7%
EPS (Diluted)
$-1.03
↑ 8.0%
Shareholders' Equity
$1.0B
↑ 191.0%
Cash & Equivalents
$524.7M
↑ 225.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 6/5/2026 | View on SEC |
| 15-12G | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/13/2026 | View on SEC |
| SCHEDULE 13G/A | 5/12/2026 | View on SEC |
| EFFECT | 5/7/2026 | View on SEC |
| 4 | 5/5/2026 | View on SEC |
| 4 | 5/5/2026 | View on SEC |
| 4 | 5/5/2026 | View on SEC |
| 4 | 5/5/2026 | View on SEC |
| 4 | 5/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TERN |
| Company Name | Terns Pharmaceuticals, Inc. |
| CIK | 1831363 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-525-5535 EXT.101 |